Campbell Tiley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4461291/publications.pdf

Version: 2024-02-01

19	598	8	14
papers ci	itations	h-index	g-index
19 all docs doc	19	19 times ranked	1033 citing authors

#	Article	IF	CITATIONS
1	Australia and New Zealand Transplant and Cellular Therapies ⟨scp⟩COVIDâ€19⟨ scp⟩ vaccination consensus position statement. Internal Medicine Journal, 2021, 51, 1321-1323.	0.8	6
2	Promising Real World Survival Data in Adult-Onset Langerhans Cell Histiocytosis: An Australasian Lymphoma Alliance 20 Year Retrospective Study. Blood, 2021, 138, 2570-2570.	1.4	1
3	A multi-center randomized controlled trial to reduce unmet needs, depression, and anxiety among hematological cancer patients and their support persons. Journal of Psychosocial Oncology, 2020, 38, 272-292.	1.2	20
4	Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study. Blood, 2020, 136, 11-12.	1.4	2
5	Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study. Blood, 2019, 134, 4150-4150.	1.4	0
6	In Vivo Assessment of Intracellular Dynamics Comparing Injection Versus Oral Azacitidine in a Phase Ilb Investigator Initiated Clinical Trial. Blood, 2019, 134, 4247-4247.	1.4	0
7	Lymphoma cellâ€of–origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts. British Journal of Haematology, 2018, 181, 272-275.	2.5	8
8	â€~Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma. Leukemia and Lymphoma, 2018, 59, 1514-1516.	1.3	11
9	The delayed diagnosis of myeloproliferative neoplasms is common and results in a high incidence of potentially preventable thrombotic complications. Pathology, 2018, 50, 775-776.	0.6	6
10	Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia. Journal of Clinical Oncology, 2017, 35, 1678-1685.	1.6	14
11	High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation. British Journal of Clinical Pharmacology, 2016, 82, 149-159.	2.4	43
12	Are Australian clinicians monitoring medication adherence in hematological cancer survivors? Two cross-sectional studies. Experimental Hematology and Oncology, 2015, 4, 15.	5 . O	4
13	Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematology,the, 2015, 2, e357-e366.	4.6	133
14	All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood, 2012, 120, 1570-1580.	1.4	268
15	A phase <scp>II</scp> study of riskâ€adapted intravenous melphalan in patients with <scp>AL</scp> amyloidosis. British Journal of Haematology, 2012, 157, 766-769.	2.5	9
16	Lower Drug Exposure Is Related to Renal Function and Results in Inferior Survival: A Pharmacokinetic Study of High Dose Melphalan in Myeloma. Blood, 2012, 120, 1979-1979.	1.4	0
17	A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, A±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC)	1.4	6
18	A Phase II Study of Risk-Adapted Intravenous Melphalan in Patients with AL Amyloidosis,. Blood, 2011, 118, 3973-3973.	1.4	1

#	Article	IF	CITATIONS
19	Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. British Journal of Clinical Pharmacology, 2010, 69, 484-497.	2.4	66